Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Nuclear Medicine Review
MENU
Shortcuts Submit an article Author Guidelines Editorial Board Reviewers 2023

open access

Vol 23, No 2 (2020)
Research paper
Submitted: 2020-03-27
Accepted: 2020-06-18
Published online: 2020-07-20
View PDF Download PDF file
Get Citation

The diagnostic value of dual-phase SPECT/CT scintigraphy based on transport kinetics of 99mTc-sestamibi confirmed with histopathological findings in patients with secondary hyperparathyroidism — practical consideration

Maria H. Listewnik1, Hanna Piwowarska-Bilska1, Krzysztof Safranow2, Marek Ostrowski3, Jacek Iwanowski1, Maria Chosia4, Bozena Birkenfeld1
DOI: 10.5603/NMR.a2020.0017
·
Pubmed: 33007093
·
Nucl. Med. Rev 2020;23(2):71-77.
Affiliations
  1. Department of Nuclear Medicine, Pomeranian Medical University in Szczecin, Szczecin, Poland
  2. Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin, Szczecin, Poland
  3. Department of General Surgery and Transplantology, Pomeranian Medical University in Szczecin, Szczecin, Poland
  4. Department of Pathology, Pomeranian Medical University in Szczecin, Unii Lubelskiej, 71-252 Szczecin, Poland

open access

Vol 23, No 2 (2020)
Original articles
Submitted: 2020-03-27
Accepted: 2020-06-18
Published online: 2020-07-20

Abstract

BACKGROUND: Dual phase 99mTc-sestamibi SPECT/CT preoperative parathyroid scintigraphy (PPS) is seldom discussed
in terms of the transport kinetics of the tracer.
Objectives: To assess the relationship between the characteristic type of tracer transport in particular PPS and histopathological
findings in patients with secondary hyperparathyroidism (sHPT).
MATERIAL AND METHODS: The study comprised 27 patients (13 females and 14 males) with sHPT. Based on tracer accumulation
in early phase (EP) and delayed phase (DP), the following types of accumulation for PPS(+) lesions were identified: EP(–)/
DP(+) (type I), EP(+)/DP(+) (type II), EP(+)/DP(–) (type III). EP(–)/DP(–) (type IV) lesions constituted PPS(–) group invisible in
SPECT/CT. Overall, 69 lesions 59 PPS(+) and 10 PPS(–) were evaluated histopathologically.
RESULTS: Among SPECT/CT PPS(+), types I, II and III occurred in 9 (15%), 49 (83%), and 1 (2%) lesions, respectively. The
frequency of histopathological diagnosis of normal and abnormal (APG — adenoma or hyperplasia) parathyroid gland, as well
as non-parathyroid (thyroid, lymph nodes, or fat) lesions differed significantly between type I, II, and III lesions (p = 0.036).
APG histopathological diagnosis was significantly more frequent in lesions with type II uptake than in lesions with type I uptake
(76% vs. 33%, p = 0.0197). Type II lesions had significantly higher odds for histopathological diagnosis of APG or NPG than
type IV, PPS(–) lesions [odds ratio = 13.1 (95% CI: 2.75 to 63.27)].
CONCLUSIONS: For SHP patients evaluated with SPECT/CT PPS accumulation type I is a weak premise for surgeon to find
parathyroid pathology. Only persistent 99mTc-sestamibi accumulation in both phases - equivocal with accumulation type II
— effectively differentiates parathyroid and non-parathyroid lesions as well as indicates with high probability the presence of
adenoma or hyperplasia. Type III consistent with washout pattern is rare in sHPT.

Abstract

BACKGROUND: Dual phase 99mTc-sestamibi SPECT/CT preoperative parathyroid scintigraphy (PPS) is seldom discussed
in terms of the transport kinetics of the tracer.
Objectives: To assess the relationship between the characteristic type of tracer transport in particular PPS and histopathological
findings in patients with secondary hyperparathyroidism (sHPT).
MATERIAL AND METHODS: The study comprised 27 patients (13 females and 14 males) with sHPT. Based on tracer accumulation
in early phase (EP) and delayed phase (DP), the following types of accumulation for PPS(+) lesions were identified: EP(–)/
DP(+) (type I), EP(+)/DP(+) (type II), EP(+)/DP(–) (type III). EP(–)/DP(–) (type IV) lesions constituted PPS(–) group invisible in
SPECT/CT. Overall, 69 lesions 59 PPS(+) and 10 PPS(–) were evaluated histopathologically.
RESULTS: Among SPECT/CT PPS(+), types I, II and III occurred in 9 (15%), 49 (83%), and 1 (2%) lesions, respectively. The
frequency of histopathological diagnosis of normal and abnormal (APG — adenoma or hyperplasia) parathyroid gland, as well
as non-parathyroid (thyroid, lymph nodes, or fat) lesions differed significantly between type I, II, and III lesions (p = 0.036).
APG histopathological diagnosis was significantly more frequent in lesions with type II uptake than in lesions with type I uptake
(76% vs. 33%, p = 0.0197). Type II lesions had significantly higher odds for histopathological diagnosis of APG or NPG than
type IV, PPS(–) lesions [odds ratio = 13.1 (95% CI: 2.75 to 63.27)].
CONCLUSIONS: For SHP patients evaluated with SPECT/CT PPS accumulation type I is a weak premise for surgeon to find
parathyroid pathology. Only persistent 99mTc-sestamibi accumulation in both phases - equivocal with accumulation type II
— effectively differentiates parathyroid and non-parathyroid lesions as well as indicates with high probability the presence of
adenoma or hyperplasia. Type III consistent with washout pattern is rare in sHPT.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

secondary hyperparathyroidism; single photon emission computed tomography; technetium-99m sestamibi; parathyroid hormone; parathyroid adenoma; hyperplasia

About this article
Title

The diagnostic value of dual-phase SPECT/CT scintigraphy based on transport kinetics of 99mTc-sestamibi confirmed with histopathological findings in patients with secondary hyperparathyroidism — practical consideration

Journal

Nuclear Medicine Review

Issue

Vol 23, No 2 (2020)

Article type

Research paper

Pages

71-77

Published online

2020-07-20

Page views

824

Article views/downloads

741

DOI

10.5603/NMR.a2020.0017

Pubmed

33007093

Bibliographic record

Nucl. Med. Rev 2020;23(2):71-77.

Keywords

secondary hyperparathyroidism
single photon emission computed tomography
technetium-99m sestamibi
parathyroid hormone
parathyroid adenoma
hyperplasia

Authors

Maria H. Listewnik
Hanna Piwowarska-Bilska
Krzysztof Safranow
Marek Ostrowski
Jacek Iwanowski
Maria Chosia
Bozena Birkenfeld

References (44)
  1. Chen JB, Chou FF, Yang CH, et al. Association between clinical variables and mortality after parathyroidectomy in maintenance hemodialysis patients. Am J Surg. 2017; 213(1): 140–145.
    CrossRefPubMed
  2. Zeng M, Liu W, Zha X, et al. 99mTc-MIBI SPECT/CT imaging had high sensitivity in accurate localization of parathyroids before parathyroidectomy for patients with secondary hyperparathyroidism. Ren Fail. 2019; 41(1): 885–892.
    CrossRef
  3. Ballinger AE, Palmer SC, Nistor I, et al. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev. 2014(12): CD006254.
    CrossRefPubMed
  4. Tominaga Y, Johansson H, Johansson H, et al. Secondary hyperparathyroidism: pathophysiology, histopathology, and medical and surgical management. Surg Today. 1997; 27(9): 787–792.
    CrossRefPubMed
  5. Konturek A, Barczyński M, Stopa M, et al. Subtotal parathyroidectomy for secondary renal hyperparathyroidism: a 20-year surgical outcome study. Langenbecks Arch Surg. 2016; 401(7): 965–974.
    CrossRefPubMed
  6. Yuan LL, Kan Y, Ma DQ, et al. Combined application of ultrasound and SPECT/CT has incremental value in detecting parathyroid tissue in SHPT patients. Diagn Interv Imaging. 2016; 97(2): 219–225.
    CrossRefPubMed
  7. Olaizola I, Zingraff J, Heuguerot C, et al. [(99m)Tc]-sestamibi parathyroid scintigraphy in chronic haemodialysis patients: static and dynamic explorations. Nephrol Dial Transplant. 2000; 15(8): 1201–1206.
    CrossRefPubMed
  8. Hindié E, Ugur O, Fuster D, et al. Parathyroid Task Group of the EANM. 2009 EANM parathyroid guidelines. Eur J Nucl Med Mol Imaging. 2009; 36(7): 1201–1216.
    CrossRefPubMed
  9. Yang J, Hao R, Yuan L, et al. Value of dual-phase (99m)Tc-sestamibi scintigraphy with neck and thoracic SPECT/CT in secondary hyperparathyroidism. AJR Am J Roentgenol. 2014; 202(1): 180–184.
    CrossRefPubMed
  10. Assante R, Zampella E, Nicolai E, et al. Incremental Value of Sestamibi SPECT/CT Over Dual-Phase Planar Scintigraphy in Patients With Primary Hyperparathyroidism and Inconclusive Ultrasound. Front Med (Lausanne). 2019; 6: 164.
    CrossRefPubMed
  11. Yip L, Pryma DA, Yim JH, et al. Can a lightbulb sestamibi SPECT accurately predict single-gland disease in sporadic primary hyperparathyroidism? World J Surg. 2008; 32(5): 784–92; discussion 793.
    CrossRefPubMed
  12. Sheu-Grabellus SY, Schmid KW. [Pathology of parathyroid glands: Practical aspects for routine pathological investigations]. Pathologe. 2015; 36(3): 229–236.
    CrossRefPubMed
  13. Uchida K, Tominaga Y, Tanaka Y, et al. Renal transplantation and secondary hyperparathyroidism. Semin Surg Oncol. 1997; 13(2): 97–103, doi: 10.1002/(sici)1098-2388(199703/04)13:2<97::aid-ssu5>3.0.co;2-x.
  14. Caldarella C, Treglia G, Pontecorvi A, et al. Diagnostic performance of planar scintigraphy using ⁹⁹mTc-MIBI in patients with secondary hyperparathyroidism: a meta-analysis. Ann Nucl Med. 2012; 26(10): 794–803.
    CrossRefPubMed
  15. Hindié E, Zanotti-Fregonara P, Just PA, et al. Parathyroid scintigraphy findings in chronic kidney disease patients with recurrent hyperparathyroidism. Eur J Nucl Med Mol Imaging. 2010; 37(3): 623–634.
    CrossRefPubMed
  16. Spanu A, Schillaci O, Piras B, et al. SPECT/CT in hyperparathyroidism. Clin Transl Imaging. 2014; 2(6): 537–555.
    CrossRef
  17. Carpentier A, Jeannotte S, Verreault J, et al. Preoperative localization of parathyroid lesions in hyperparathyroidism: relationship between technetium-99m-MIBI uptake and oxyphil cell content. J Nucl Med. J Nucl Med. 1998; 39(8): 1441–1444.
    PubMed
  18. Rutkowski B, Ciechanowski K, Durlik M, et al. Availability of different therapeutic option in patients with secondary hyperthyroidism in Poland. Forum Nefrol. 2012; 5(4): 333–338.
  19. Tominaga Y, Tanaka Y, Sato K, et al. Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Seminars in Surgical Oncology. 1997; 13(2): 78–86, doi: 10.1002/(sici)1098-2388(199703/04)13:2<78::aid-ssu3>3.0.co;2-z.
  20. DeLellis RA. Parathyroid tumors and related disorders. Mod Pathol. 2011; 24 Suppl 2: S78–S93.
    CrossRefPubMed
  21. Zitt E, Lhotta K. [Management of secondary hyperparathyroidism-current impact of parathyroidectomy]. Wien Med Wochenschr. 2016; 166(7-8): 254–258.
    CrossRefPubMed
  22. Coakley AJ, Kettle AG, Wells CP, et al. 99Tcm sestamibi--a new agent for parathyroid imaging. Nucl Med Commun. 1989; 10(11): 791–794.
    CrossRefPubMed
  23. Taillefer R, Boucher Y, Potvin C, et al. Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99m-sestamibi (double-phase study). J Nucl Med. 1992; 33(10): 1801–1807.
    PubMed
  24. Bénard F, Lefebvre B, Beuvon F, et al. Rapid washout of technetium-99m-MIBI from a large parathyroid adenoma. J Nucl Med. 1995; 36(2): 241–243.
    PubMed
  25. Perez-Monte JE, Brown ML, Shah AN, et al. Parathyroid adenomas: accurate detection and localization with Tc-99m sestamibi SPECT. Radiology. 1996; 201(1): 85–91.
    CrossRefPubMed
  26. Lorberboym M, Minski I, Macadziob S, et al. Incremental diagnostic value of preoperative 99mTc-MIBI SPECT in patients with a parathyroid adenoma. J Nucl Med. 2003; 44(6): 904–908.
    PubMed
  27. Fröberg AC, Valkema R, Bonjer HJ, et al. 99mTc-tetrofosmin or 99mTc-sestamibi for double-phase parathyroid scintigraphy? Eur J Nucl Med Mol Imaging. 2003; 30(2): 193–196.
    CrossRefPubMed
  28. Vulpio C, Bossola M, De Gaetano A, et al. Usefulness of the combination of ultrasonography and 99mTc-sestamibi scintigraphy in the preoperative evaluation of uremic secondary hyperparathyroidism. Head Neck. 2010; 32(9): 1226–1235.
    CrossRefPubMed
  29. Liu Y, Chun KJ, Freeman LM. 'Shine through' on dual tracer parathyroid scintigraphy: a potential pitfall in interpretation. Clin Nucl Med. 2005; 30(3): 145–149.
    CrossRefPubMed
  30. Zhen L, Li H, Liu X, et al. The application of SPECT/CT for preoperative planning in patients with secondary hyperparathyroidism. Nucl Med Commun. 2013; 34(5): 439–444.
    CrossRefPubMed
  31. Taïeb D, Ureña-Torres P, Zanotti-Fregonara P, et al. Parathyroid scintigraphy in renal hyperparathyroidism: the added diagnostic value of SPECT and SPECT/CT. Clin Nucl Med. 2013; 38(8): 630–635.
    CrossRefPubMed
  32. Monzen Y, Tamura A, Okazaki H, et al. SPECT/CT Fusion in the Diagnosis of Hyperparathyroidism. Asia Oceania J Nucl Med Biol. 2015; 3(1): 61–65.
    PubMed
  33. Souberbielle JC. Measurement of Parathormone in Chronic Kidney Disease: An Easy Task? In: Delanaye P. ed. Nephrology and Clinical Chemistry: The Essential Link. Bentham Books, Belgium 2012: 91–105.
  34. Bolasco P, Serra A, Loi M, et al. Failed Switching off in the MIBI-Parathyroid Scintigraphy in a Dialyzed Patient with Secondary Hyperparathyroidism Responsive to Cinacalcet Therapy. Int J Endocrinol. 2010; 2010: 206801.
    CrossRefPubMed
  35. Raruenrom Y, Theerakulpisut D, Wongsurawat N, et al. Diagnostic accuracy of planar, SPECT, and SPECT/CT parathyroid scintigraphy protocols in patients with hyperparathyroidism. Nucl Med Rev Cent East Eur. 2018; 21(1): 20–25.
    CrossRefPubMed
  36. Fang Li, Tang B, Hou D, et al. Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism. BMC Nephrol. 2015; 16: 82.
    CrossRefPubMed
  37. Rosato L, Raffaelli M, Bellantone R, et al. Diagnostic, therapeutic and healthcare management protocols in parathyroid surgery: II Consensus Conference of the Italian Association of Endocrine Surgery Units (U.E.C. CLUB). J Endocrinol Invest. 2014; 37(2): 149–165.
    CrossRefPubMed
  38. Del Vecchio S, Zannetti A, Aloj L, et al. MIBI as prognostic factor in breast cancer. Q J Nucl Med Mol Imaging. 2003; 47(1): 46–50.
    PubMed
  39. Kasai ETP, da Silva JWE, Mandarim de Lacerda CA, et al. Parathyroid glands: combination of sestamibi-(99m)Tc scintigraphy and ultrasonography for demonstration of hyperplasic parathyroid glands. Rev Esp Med Nucl. 2008; 27(1): 8–12.
    CrossRefPubMed
  40. Kao A, Shiau YC, Tsai SC, et al. Technetium-99m methoxyisobutylisonitrile imaging for parathyroid adenoma: relationship to P-glycoprotein or multidrug resistance-related protein expression. Eur J Nucl Med Mol Imaging. 2002; 29(8): 1012–1015.
    CrossRefPubMed
  41. Yamaguchi S, Kobayashi Y, Tsujikawa K, et al. [Usefulness of 99mTc-methoxy-isobutyl-isonitrile scintigraphy for preoperative localization of adenoma in primary hyperparathyroidism]. Hinyokika Kiyo. 2001; 47(9): 619–623.
    PubMed
  42. Shevtsova ON, Shevtsova VK. Mathematical Simulation of Transport Kinetics of Tumor-Imaging Radiopharmaceutical Tc-MIBI. Comput Math Methods Med. 2017; 2017: 2414878.
    CrossRefPubMed
  43. Listewnik M, Piwowarska-Bilska H, Kurzawski M, et al. The relationship of mRNA ABCC1 expression and uptake of MIBI-Tc99m in patients with hyperparathyroidism. (Meeting Abstract). Eur J Nucl Med Mol Imaging . 2016; 43(S70): WOS:000391801600160.
  44. Xue J, Liu Y, Yang D, et al. Dual-phase 99mTc-MIBI imaging and the expressions of P-gp, GST-π, and MRP1 in hyperparathyroidism. Nucl Med Commun. 2017; 38(10): 868–874.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

phone: +48 58 320 94 94, fax: +48 58 320 94 60, e-mail: viamedica@viamedica.pl